Investing Ideas
/
Hong Kong Pharmaceuticals & Biotech Strong Past Earnings Growth, P/E Ratio Below 20

Hong Kong Pharmaceuticals & Biotech Strong Past Earnings Growth, P/E Ratio Below 20

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

0 new

A list of companies that grew earnings by 20% and are trading on less than 20 times earnings. All with a debt to equity ratio below 1.

6 companies

Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield
3933 United Laboratories International Holdings	HK$11.54	1.2%	67.0%	HK$21.0b	HK$12.11	PE6.7x	E5.2%	5.2%
6826 Shanghai Haohai Biological Technology	HK$24.80	-0.6%	6.8%	HK$12.7b	HK$42.57	PE12.3x	E16.8%	3.5%
1558 YiChang HEC ChangJiang Pharmaceutical	HK$9.19	0.4%	11.8%	HK$8.1b	HK$12.59	PE4.6x	S-1.2%	0%
2877 China Shineway Pharmaceutical Group	HK$8.28	0%	6.0%	HK$6.3b	HK$13.01	PE5.3x	E5.5%	6.8%
2348 Dawnrays Pharmaceutical (Holdings)	HK$1.20	0%	8.1%	HK$1.8b	n/a	PE3x	n/a	6.5%
2566 Hangzhou Jiuyuan Gene Engineering	HK$5.84	3.4%	n/a	HK$1.4b	n/a	PE10.4x	n/a	n/a

Page 1 of 1